ArticleOpen forum infectious diseases2016
Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s.
Open access · goldAbstract read
In one paragraph
Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis.BMJ open diabetes research & care · 2023Pooled it
- Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.Journal of acquired immune deficiency syndromes (1999) · 2021Trial
- TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study.The lancet. HIV · 2026Article
- A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV.Structure (London, England : 1993) · 2025Article
- No Genetic Causal Relationship Between HIV Infection and Insulin Resistance, Diabetes: A Bidirectional Mendelian Randomization Analysis.Journal of multidisciplinary healthcare · 2025Article
- Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.BMC infectious diseases · 2024Article
- Waist circumference and cardiometabolic parameters in people of African/Caribbean ancestry with HIV in South London (CKD-AFRICA study).International journal of STD & AIDS · 2024Article
- Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas.Life (Basel, Switzerland) · 2024Review
- Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV.Endocrine reviews · 2024Review
- Risks of metabolic syndrome in the ADVANCE and NAMSAL trials.Frontiers in reproductive health · 2023Article
- Metabolic Consequences of Antiretroviral Therapy.Current HIV/AIDS reports · 2022Review
- Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.The Journal of clinical endocrinology and metabolism · 2022Article
- Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection.Open forum infectious diseases · 2021Article
- Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment.Frontiers in immunology · 2021Review
- Metabolic changes in the patients on second-line highly active antiretroviral therapy (HAART): A prospective cohort study from north India.Journal of family medicine and primary care · 2020Article
- Antiretroviral Therapy-Associated Metabolic Complications: Review of the Recent Studies.HIV/AIDS (Auckland, N.Z.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Sahera Dirajlal-FargoDepartment of Pediatric/Infectious Diseases and Rheumatology , Case Western Reserve University , Cleveland, Ohio.
Carlee MoserHarvard School of Public Health, Boston, Massachusetts.
Todd T BrownDepartment of Medicine/Endocrinology and Metabolism , Johns Hopkins University , Baltimore, Maryland.
Theodoros KelesidisDepartment of Medicine/Infectious Diseases , UCLA , Los Angeles, California.
Michael P DubeDepartment of Medicine , University of Southern California Keck School of Medicine , Los Angeles.
James H SteinDepartment of Medicine , University of Wisconsin School of Medicine and Public Health , Madison.
Judith CurrierDepartment of Medicine/Infectious Diseases , UCLA , Los Angeles, California.
Grace A McComseyDepartment of Pediatric/Infectious Diseases and Rheumatology , Case Western Reserve University , Cleveland, Ohio.
Case Western Reserve University · USHarvard University · USJohns Hopkins University · USUniversity of Southern California · USUniversity of Wisconsin–Madison · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MAIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1MStatistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9MInstitute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1MClinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0MCase Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4MNorthwestern University Clinical Trial UnitUM1AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach · 2012 to 2026
$24.6MCase AIDS Clinical Trials UnitU01AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEDERMAN, MICHAEL MARCEL · 2007 to 2011
$14.7MNorthwestern University Clinical Trial UnitU01AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MURPHY, ROBERT LEO · 2007 to 2011
$12.0MCVD and Metabolic Complications of HIV/AIDS Data Coordinating CenterR01HL095126 · NHLBI · UNIVERSITY OF WASHINGTON · PI KRONMAL, RICHARD A · 2008 to 2012
$5.9MProspective Evaluation of Antiviral Therapy and Cardiac HealthR01HL095132 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S., STEIN, JAMES H · 2008 to 2012
$4.0MNCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR001079NHLBI NIH HHS R01 HL095126NHLBI NIH HHS R01 HL095132NIAID NIH HHS K08 AI108272NIAID NIH HHS K24 AI056933NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069471NIAID NIH HHS U01 AI069501NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI069501NICHD NIH HHS K23 HD088295
Abstract
PubMed holds no abstract for this paper.
Indexed as
inflammatory markersinsulin resistanceraltegravir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.